Search results
Results from the WOW.Com Content Network
Anil Potti is a physician and former Duke University associate professor and cancer researcher, focusing on oncogenomics. He, along with Joseph Nevins, are at the center of a research fabrication scandal at Duke University. [1] [2] [3] On 9 November 2015, the Office of Research Integrity (ORI) found that Potti had engaged in research misconduct ...
The American Cancer Society, a non-profit organization dedicated to eliminating the disease, called on the administration to "restore access to comprehensive data, refrain from changes that would ...
The HPV vaccine has the most misinformation of any vaccine, research suggests. ... Between 2012 and 2019, cervical cancer incidence among women ages 20 to 24 dropped by 65%, ...
There is plenty of research suggesting that a person’s diet can affect their risk of cancer, particularly gastrointestinal cancers. Recent studies now add to that evidence, showing how different ...
For example, The Cancer Letter reported extensively on problems between the MD Anderson Cancer Center and the Texas state taxpayer-funded Cancer Prevention and Research Institute of Texas (CPRIT), based in Austin, after MD Anderson president Ronald DePinho "launched a drug-discovery center, the Institute for Applied Cancer Science (IACS), where ...
Sidney Farber is regarded as the father of modern chemotherapy.. Cancer research has been ongoing for centuries. Early research focused on the causes of cancer. [1] Percivall Pott identified the first environmental trigger (chimney soot) for cancer in 1775 and cigarette smoking was identified as a cause of lung cancer in 1950.
Breast cancer rates in women under the age of 40 are rising across the united states — and in some regions surging 32%.. Researchers from Columbia University’s Mailman School of Public Health ...
Dennis Joseph Slamon (born August 6, 1948), [1] [2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA.He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.